New Prostate Cancer Test Could Be 90 Per Cent Accurate
The preliminary results of a pilot study presented at the conference in the U.S. this week, the controversy surrounding screening for prostate cancer may be the situation changes: The British company has developed a panel of biomarkers, which appears to distinguish between samples of prostate cancer from benign prostate samples and healthy tissue prostate 90 percent of the time, significantly higher than current diagnostic tests.
Oxford Gene Technology (OGT) said in their pilot study involving 73 prostate cancer and 60 control samples, they identified a set of biomarkers that differentiated prostate cancer from the control samples and the sensitivity and specificity above 90 percent. "
Company vice president, Discovery of biomarkers, Dr. John Anson, presented the findings at the Fourth American Association for Cancer Research International Conference: Molecular Diagnostics in Cancer Therapeutic Development, which will be held from September 27-30 in Denver.
For the pilot study, CDP said in a statement that they tested their newly developed "functional protein" chip platform called Sense Proteomic, which uses more than a thousand "correctly folded proteins to detect antibodies in serum samples of prostate cancer."
Autoantibodies are antibodies that attack the immune system produces its own proteins the body, such as in lupus and type 1 diabetes. But cancer can also cause the immune system to create antibodies, because changes in normal proteins.
Anson told Reuters in a telephone interview that their test is looking for higher levels of these autoantibodies as early signs of disease. He also said the test could potentially be used to detect other cancers.
In a statement he said the CGT was very pleased with their initial findings: so that they have already been established subsequent clinical study using 1800 samples to develop and test the panel of biomarkers.
CGT said the new court will use the 400 samples of prostate cancer, an equal number corresponds to the normal samples, 150 samples of other types of cancer, as well as several hundred samples from patients with other diseases of the prostate.
It is currently the most effective test for prostate cancer, PSA (short for prostate specific antigen) only uses one biomarker that could lead to false positive results and cause unnecessary biopsies and treatment as a non-cancerous prostate diseases can also raise PSA levels.
Thus, including non-cancerous prostate diseases are more CDP expect the court to show that their new panel of biomarkers can tell the difference between prostate cancer and these other diseases.
CDP said results of a new trial must be in the first half of 2011. Anson said, based on pilot study results and the larger vessels, they are already looking at opportunities to partner with the diagnostic and pharmaceutical companies to develop a diagnostic test.
"We are also exploring the vast potential of our sense of Proteomic functional protein array technology to improve the diagnosis of other types of cancer and autoimmune diseases," he added.
If more research is successful, the company expects that the tests will be available for use in clinical practice for about 5 years, reports Reuters.
Over a quarter of a million people die every year worldwide due to prostate cancer. This disease is the second most common cause of cancer death among men in the U.S., where an estimated 32,000 die from it this year.
Current PSA test specificity of only less than 50 percent, resulting in many unnecessary procedures, as well as a lot of uncertainty, stress and anxiety for the patients concerned. After the biopsy also carries risks as other surgical procedures and radiotherapy.
CDP said that it is also testing its functional protein microarray technology to study in systemic lupus erythematosus (SLE) and non-small cell lung cancer cells.
The company says the technology can also be used to monitor the immune response to drugs in clinical trials that allow pharmaceutical companies to place outside the target effects of new treatments and to develop companion diagnostics.